Medtronic announced financial results for its fourth quarter and full 2025 fiscal year on Wednesday. Here are three things to know:

Driving growth

We had a strong close to our fiscal year, exceeding expectations for both revenue and EPS. We continued to build momentum in the fourth quarter thanks to a broad range of growth drivers, including the Affera™ pulsed field ablation system, which treats atrial fibrillation, and our BrainSense™ Adaptive deep brain stimulator for people with Parkinson’s disease. Our growth also spanned geographies, with revenue increasing in the U.S., Japan, Western Europe, and more.

Momentum building

We’re making progress toward expanding access to other innovative technologies and growth drivers, including our Hugo™ Robotic Assisted Surgery system. Hugo is now available in 30 countries, and we recently filed for U.S. Food and Drug Administration (FDA) approval of the technology for use in urology. Our Symplicity™ procedure for high blood pressure is also nearing key milestones. The U.S. Centers for Medicare and Medicaid Services (CMS) has indicated that it will make a key reimbursement decision on the technology by mid-October. And, our Cardiac Ablation Solutions (CAS) business had another strong quarter, reaching $1B in revenue in FY25. CAS and our ENT business now join the billion-dollar revenue club, alongside 10 other businesses across Medtronic.

Announcing our guidance and dividend

Looking forward to our 2026 fiscal year, we’re optimistic about delivering continued growth. We announced our revenue and earnings per share guidance, and also raised our dividend.

L009-05202025

Related content

Reading your brain waves to treat a debilitating disease

Can math help detect heart disease even before you know you’re sick?

Medical insertable heart monitor outperforms consumer wearable in study